UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 26, 2019

 

CORMEDIX INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-34673   20-5894890

(State of other jurisdiction of

incorporation or organization)

  (Commission File Number)  

(I.R.S. Employer

Identification No.)

 

400 Connell Drive, Suite 5000

Berkeley Heights, NJ

  07922
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (908) 517-9500

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2, below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, $0.001 par value   CRMD   NYSE American LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

As described in Item 5.07 of this Current Report on Form 8-K, on November 26, 2019, at its Annual Meeting of Stockholders for the fiscal year ending December 31, 2019 (the “Annual Meeting”), the stockholders of CorMedix Inc. (the “Company”) approved the 2019 Omnibus Stock Incentive Plan (the “2019 Incentive Plan”).

 

For a description of the terms and conditions of the 2019 Incentive Plan, as approved by stockholders on November 26, 2019, see “Summary of the 2019 Plan” under “Proposal No. 2 – Approval of the 2019 Omnibus Stock Incentive Plan” in the Definitive Proxy Statement on Schedule 14A for the Company’s Annual Meeting, filed with the Securities and Exchange Commission on October 17, 2019 (the “Proxy Statement”), which description is incorporated herein by reference.

 

The foregoing description of the 2019 Incentive Plan and the description of the 2019 Incentive Plan contained in the Proxy Statement are each qualified in their entirety by reference to the full text of the 2019 Incentive Plan, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On November 26, 2019, the Company held its Annual Meeting. Holders of shares of the Company’s common stock, Series E Preferred Stock and Series G Preferred Stock were entitled to vote at the Annual Meeting. The Company’s stockholders voted on the following three proposals at the Annual Meeting, casting their votes as described below.

 

Proposal 1. – Election of Directors. The following individuals, each of whom was named as a nominee in the Proxy Statement, were elected by the Company’s stockholders by a plurality of votes cast to serve on the Company’s board of directors until the Company’s 2020 annual meeting of stockholders. Information on the vote relating to each director standing for election is set forth below:

 

Nominee   FOR   WITHHELD   BROKER NON-VOTES
Khoso Baluch   7,970,317   1,244,579   13,605,872
Janet Dillione   8,507,304   707,592   13,605,872
Alan Dunton   8,656,188   558,708   13,605,872
Myron Kaplan   8,567,975   646,921   13,605,872
Mehmood Khan   7,547,288   1,667,608   13,605,872
Steven Lefkowitz   8,785,993   428,903   13,605,872

 

Proposal 2. – Approval of 2019 Incentive Plan. Proposal 2 was to approve the adoption of the 2019 Incentive Plan. The proposal was approved.

 

FOR   AGAINST   ABSTAIN   BROKER NON-VOTES
7,159,127   1,997,918   57,851   13,605,872

 

Proposal 3. – Ratification of Appointment of Auditors. Proposal 3 was to ratify the appointment of Friedman LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019. The proposal was approved.

 

FOR   AGAINST   ABSTAIN
21,760,627   384,439   675,702

 

1

 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
   
10.1   2019 Omnibus Stock Incentive Plan

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CORMEDIX INC.
     
Date: November 27, 2019 By: /s/ Khoso Baluch
  Name:  Khoso Baluch
  Title: Chief Executive Officer

 

 

3

 

CorMedix (AMEX:CRMD)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more CorMedix Charts.
CorMedix (AMEX:CRMD)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more CorMedix Charts.